Johnson & Johnson (JNJ) has moved into U.S. soft tissue robotic surgery after the FDA granted De Novo authorization for its OTTAVA Robotic Surgical System, a table-integrated platform cleared for multiple general surgery procedures.

See our latest analysis for Johnson & Johnson.

Against this backdrop, Johnson & Johnson’s share price has climbed steadily, with a 30 day share price return of 8.44% and a year to date share price return of 25.04%. The 1 year total shareholder return of 56.73% points to strong momentum building around the stock.

If the OTTAVA approval has you thinking more broadly about surgical technology, this is a good moment to scan other robotics and automation opportunities using the Simply Wall St screener for 33 robotics and automation stocks

After such a strong run, driven in part by Johnson & Johnson’s OTTAVA approval and higher 2026 sales guidance, the real issue now is whether today’s price still offers an appealing balance between potential upside and downside risk.

Most Popular Narrative: 12.3% Overvalued

According to the most followed narrative on Johnson & Johnson, the fair value sits at $230.82 compared with the last close of $259.27, which frames the current debate around the stock.

AI-augmented MedTech (robotics, imaging analytics), premium device pricing + subscriptions.

Read the complete narrative.

Curious what kind of growth and margin profile could justify that fair value gap for Johnson & Johnson? The narrative focuses on a richer product mix, higher productivity and premium pricing assumptions that may surprise you when seen in full.

Result: Fair Value of $230.82 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Johnson & Johnson narrative could be knocked off course if regulators push back on AI driven evidence or if faster moving competitors seize the AI lead.

Find out about the key risks to this Johnson & Johnson narrative.

Another View on Johnson & Johnson’s Valuation

While the most popular community narrative sees Johnson & Johnson as 12.3% overvalued at $259.27 versus a fair value of $230.82, the SWS DCF model points in the opposite direction, suggesting the stock is trading about 33.2% below an estimated future cash flow value of $388.31.

This kind of split view, with one approach flagging overvaluation and another implying a discount, raises the question of which lens investors may choose to rely on when considering Johnson & Johnson’s AI and MedTech ambitions.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Johnson & Johnson for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 38 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such mixed signals around Johnson & Johnson, this is a moment to move quickly, review the underlying data yourself, and weigh both the concerns and potential upsides highlighted in the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Johnson & Johnson?

If Johnson & Johnson has sharpened your focus on quality and risk, do not stop here. Expand your watchlist with a few focused stock ideas.

• Target reliable income by scanning companies that qualify as 7 dividend fortresses and see which payouts might fit a long term portfolio.
• Spot potential mispriced opportunities by reviewing the 38 high quality undervalued stocks and compare them with how Johnson & Johnson is currently assessed.
• Strengthen your downside protection by checking companies in the 79 resilient stocks with low risk scores and see which profiles line up with your risk tolerance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.